ºÚÁÏÍø´óʼÇ

About this webinar:

In Australia, women of childbearing age (15-44 years) who inject drugs are 53% less likely to receive treatment for hepatitis C virus (HCV) than women aged 45 and over. Studies conducted overseas show that direct-acting antivirals are safe and effective when taken in the third trimester of pregnancy, offering a way to mitigate gendered inequities in HCV outcomes. This seminar presents findings from a qualitative study exploring Australian healthcare provider perspectives on treating HCV in pregnancy. It examines views on clinical management, barriers to implementation, and the design of integrated care models that could support more equitable and timely access to treatment for pregnant people affected by HCV. Insights shared will inform more inclusive, timely, and effective care pathways for parents with substance use challenges.

About this speaker:

Grace Burton-McKeich is a Research Assistant in the Viral Hepatitis Clinical Research Program at the Kirby Institute, ºÚÁÏÍø´óÊÂ¼Ç Sydney, where she contributes to qualitative studies focused on improving care for people affected by HCV. She holds an Honours degree in Health Sciences from the University of Auckland and has a strong interest in health equity, particularly in supporting more inclusive, person-centred models of care for underserved populations. Grace is committed to research that informs practical, systems-level improvements in infectious disease care and access.